Project Grant HT9425261E305
Award Date 7/1/26
Completion Date 6/30/29
Dollars Obligated $752K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02215, USA
Similar Awards
- Federal Project Grant Award Summary Dana-Farber Cancer Institute, Inc. received a $1.12M project grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), effective September 1, 2026, through August 31, 2030. The award funds resource development initiatives designed to improve clinical and research outcomes for blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare hematologic malignancy. As a premier academic medical research...
- Federal Grant Award Summary Dana-Farber Cancer Institute, Inc. (DFCI) received a $1.424 million Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), awarded August 1, 2025, with a performance period through July 31, 2029. The award supports research to expand the targetable tumor antigen repertoire of renal cell carcinoma, positioning the work within DHA's broader portfolio of hypothesis-driven biomedical research...
- The Defense Health Agency has awarded a $657,263 project grant under the Military Medical Research and Development program (CFDA 12.420) to the Dana-Farber Cancer Institute, Inc. (d.b.a. DFCI) in Boston, MA. The award, effective September 1, 2024 through August 31, 2027, will support DATA-DRIVEN BIOMARKER-INFORMED DECISION ANALYTICS IN MELANOMA: IMPROVING EFFICACY AND REDUCING TOXICITY OF IMMUNE CHECKPOINT BLOCKADE. Through this grant, DFCI will conduct research to develop data-driven...
- Federal Grant Award Summary Dana-Farber Cancer Institute, Inc. (DFCI) received a $560K project grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) to support the development of novel digenic combination therapies for pancreatic cancer treatment. The award, effective September 1, 2026, through August 31, 2028, funds research and development activities conducted at DFCI's Boston, Massachusetts facility. This research initiative...
- Federal Project Grant Award Summary Massachusetts General Hospital (MGH) received a $1.35M project grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) awarded on July 1, 2026, with a completion date of June 30, 2029. The award funds research to develop explainable artificial intelligence (AI) systems for predicting melanoma progression and survival outcomes. This research aligns with the Defense Health Agency's mission to advance...
- Federal Project Grant Award Summary Dana-Farber Cancer Institute, Inc. (DFCI) received a $1.1M project grant from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) effective June 1, 2026, through May 31, 2030. The award supports research and development activities for the "LISTEN: Augmenting and Facilitating Communication in Brain Tumor Patients with Aphasia" initiative, conducted at DFCI's Boston, Massachusetts location. Under this four-year...
- Federal Grant Award Summary Dana-Farber Cancer Institute, Inc. received a $1,099,614 Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) effective June 1, 2026 through May 31, 2030. The award supports research to define a retinoblastoma (RB) functional subtype of endometrial cancer, contributing to the Defense Health Agency's broader mission of transforming healthcare for service members and the American public through innovative...
- Dana-Farber Cancer Institute, Inc. (DFCI) received a $711,821 Project Grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) for the period of October 1, 2025 through September 30, 2027. The award supports research into the molecular pathways of uveal melanoma dormancy, a hypothesis-driven investigation designed to advance understanding of melanoma biology and inform therapeutic development. This research aligns with the DHA's...
- Federal Grant Award Summary Dana-Farber Cancer Institute, Inc. received a $4.2 million Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) effective September 1, 2026, through August 31, 2030. The award supports research and development of optimized B7-H3 chimeric antigen receptor (CAR) T cell therapies targeting children and young adults with sarcomas and other B7-H3-positive solid tumors. The research will be conducted at the...
- The federal Project Grant award of $2,136,000.00 was provided by the Defense Health Agency through the Military Medical Research and Development program (CFDA 12.420) to the Dana-Farber Cancer Institute, Inc. (DFCI) in Boston, Massachusetts. The grant supports research aimed at understanding and therapeutically targeting treatment-emergent neuroendocrine prostate cancer. As a leading academic medical research institution, DFCI will leverage its expertise in oncology, immunology, molecular...